News & Updates
Filter by Specialty:
Hybrid, bismuth quadruple therapies superior to high-dose dual therapy for H pylori eradication
In the first-line treatment of Helicobacter pylori (H pylori) infection, 14-day hybrid therapy and 10-day bismuth quadruple therapy demonstrate superiority over 14-day high-dose dual therapy, reports a Taiwan study. However, high-dose therapy results in fewer adverse events than hybrid bismuth quadruple therapies.
Hybrid, bismuth quadruple therapies superior to high-dose dual therapy for H pylori eradication
03 Aug 2023
Abrocitinib effectively controls AD regardless of dosing regimen
In patients with moderate-to-severe atopic dermatitis (AD), flexible dosing of abrocitinib, an oral, once-daily Janus kinase 1-selective inhibitor, appeared as beneficial as the continuous high-dose regimen. This was demonstrated in a post hoc analysis of two studies from the JADE* clinical development programme.
Abrocitinib effectively controls AD regardless of dosing regimen
03 Aug 2023
Awareness is key to preventing lipohypertrophy in diabetic patients on insulin
A study on adult patients with type 2 diabetes mellitus (T2DM) treated with insulin for at least 6 months showed 2-in-5 patients had lipohypertrophy.
